PDF) Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Richard NEAR, Research Assistant Professor, phd, Boston University, MA, BU, Department of Medicine

Enhancing FcγR-mediated antibody effector function during persistent viral infection

The Current Landscape of Antibody-based Therapies in Solid Malignancies

Enhancing FcγR-mediated antibody effector function during persistent viral infection

FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications

Site-Specific Glycosylation Mapping of Fc Gamma Receptor IIIb from Neutrophils of Individual Healthy Donors

Frontiers Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking

PDF) Beyond antibody fucosylation: α-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy

Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer

Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis. - Abstract - Europe PMC

Inhibiting N‐glycan processing increases the antibody binding affinity and effector function of human natural killer cells - Rodriguez Benavente - 2023 - Immunology - Wiley Online Library